However, as pan-LXR agonists are able to induce the expression of target genes of both LXRα and LXRβ, they have adverse effects, including hepatic TG accumulation and hypertriglyceridaemia, limiting their therapeutic application [27]. This evidence concerns the gene NR1H3 and hypertriglyceridemia.